Intech Biopharm Ltd (6461.TWO) stock: key figures, P/E, revenue and dividend

Health Care · Biotechnology · Taiwan · ISIN TW0006461007

Price
26.40 TWD
Market cap
2.91 bn TWD
P/E (2025)
–
P/S (2025)
27.09
Dividend yield
0.00 %
Net margin
-361.80 %
Return on equity (ROE)
-35.33 %
Return on assets (ROA)
-16.55 %

Intech Biopharm Ltd financials

Fiscal year20242025
Revenue39.78 m TWD107.53 m TWD
Gross profit-157.63 m TWD-110.94 m TWD
Operating income-356.13 m TWD-364.50 m TWD
EBIT-334.05 m TWD-348.71 m TWD
Net income-368.21 m TWD-389.03 m TWD
Diluted EPS – continuing operations-2.63 TWD-2.18 TWD

Full history since 2017, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Intech Biopharm Ltd

Intech Biopharm Corporation engages in developing and manufacturing generic drugs to treat respiratory diseases in Taiwan and internationally. The company offers combinations, formulations, and generic drugs for the treatment of respiratory diseases using technology platforms, such as inhaled low ethanol formulation, a metered dose inhaler platform for treating asthma and COPD, as well as dry powder inhaler that comprises blisters and capsules. Its products include SYN006, SYN010, SYN007, Synflutide, Duasma,Synvent, and SYN011. The company was founded in 2010 and is headquartered in Taipei, Taiwan.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 30.10.2026. Details in the risk notice.